Anthera Pharmaceuticals, Inc. (ANTH)

[Obelax]

News!!!

Anthera Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

Source: PR Newswire (US)
HAYWARD, Calif., Feb. 10, 2015 /PRNewswire/ -- Anthera Pharmaceuticals (NASDAQ: ANTH) today announced that the company has received formal notification from the Nasdaq Stock Market ("Nasdaq"), indicating that the Company has regained compliance with Listing Rule 5450(b)(1)(A), which requires a minimum of $10,000,000 in stockholders' equity or maintaining a market value of $50,000,000 or greater for ten consecutive business days. Nasdaq has determined that Anthera has maintained market value of at least $50,000,000 for the last ten consecutive business days and as such, the Company has met alternative listing requirements for continued listing.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious and life-threatening diseases, including systemic lupus erythematosus, IgA nephropathy, and exocrine pancreatic insufficiency due to cystic fibrosis.